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Global developmental delay is defined as delay in two or more of the following 
developmental domains: Gross/ Fine motor, Speech/ Language, Cognition, Social/ 
Personal and Activity of Daily Living (ADL). Global developmental delay, which 
affects one to three percent of all children typically under the age of 5 years, describes 
a clinical presentation that has a heterogeneous etiologic profile (1); this term usually 




Neurodevelopmental disability is one of the most common problems of children 
referred to Pediatric Neurology Clinics. These children may suffer from speech 
delay, intellectual deficiency and behavioral disorder. 
Some patients with neurodevelopomental delay, especially those with intellectual 
disability and speech problems, have abnormal electroencephalograms, without 
clinical seizure. It seems that treating these patients with antiepileptic drugs 
normalizes the EEG, thereby preventing the electrical paroxysmal discharges 
that could be harmful for the developing brain. Several studies reported the 
use of Valproate, Lamotrigine and Corticosteroid in suppression of subclinical 
epileptiform discharges and improvement of developmental behavioral 
conditions. 
In our experiences, oral Na-Valproate was effective in developmental behavioral 
condition of children with neurodevelopmental delay and elimination of 
subclinical EEG discharges after 18 months of treatment.
Also we used high dose intravenous methyl - prednisolone in a group of 
children with neurodevelopmental delay and electrical status epilepticus 
during slow - wave sleep without clinical seizure. In these children results of the 
appropriate neuro-metabolic tests and magnetic resonance imaging of the brain 
revealed no abnormality. Because no underlying etiology could be determined, 
isolated non convulsive status epilepticus was established. After treatment no 
significant response was observed in these group of children. 
In another study we used Lamotrigine in children with neurodevelopmental 
delay, abnormal epileptiform discharges but without clinical seizures. Our 
results revealed Lamotrigine provides effective control of both subclinical 
epileptiform discharges and behavioral disorder, without improvement in their 
cognition. Further studies are needed to investigate and confirm the cognitive and 
behavioral effects of Lamotrigine in children with psychomotor retardation. 
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refers to younger children, whereas the term mental 
retardation is usually applied to older children when IQ 
testing is more valid and reliable (1). Significant delay is 
defined as performance two standard deviations or more 
below the mean on age-appropriate standardize norm 
testing. Behavior is defined as “anything that an organism 
does involving action and response to stimulation”. The 
definition implies that human behaviors are the results 
of interactive processes between the individual and the 
environment.
Environmental influences such as culture, parental 
skills and neglect may modify the expression as well 
as the detection and diagnosis of global developmental 
delay. Evidence also demonstrates the benefits of early 
intervention through a variety of programs, and suggests 
that early diagnosis of a child with global delay may 
improve outcome. Given the higher incidence of epilepsy 
and behavioral disorder in children with developmental 
delay, EEG is often considered an initial evaluation. 
Cognitive impairment and Subclinical 
epileptiform discharges 
Interictal discharges can occur silently without 
apparent simultaneous clinical manifestations. Formal 
testing during electroencephalographic recording may 
demonstrate transitory cognitive impairment (TCI) (2). 
Such cognitive impairment occurs exclusively in direct 
relation to episodes of epileptiform EEG discharges and 
must be distinguished from postictal seizure effects.
Existing epidemiological data reveal a low prevalence 
for cognitive impairment during epileptiform EEG 
discharges. In one study, 2.2% of the patients referred 
to a specialized epilepsy center for EEG recording, 
showed a definite relationship between epileptiform 
EEG discharges and cognitive impairment (transient 
cognitive impairment) (3). Short epileptiform discharges 
of 10 seconds or less in children with or without epilepsy 
are not noticed by clinical observation of the child. 
Transitory cognitive impairment (TCI) can often be 
detected during even brief discharges, including single 
spikes. 
In addition some studies have indicated that such mild 
effects may accumulate over time (when frequent 
epileptiform EEG discharges persist over years) and 
consequently result in deterious effects on stable aspects 
of cognitive function (4).
Several studies have been performed to show the negative 
effects of these epileptiform electroencephalographic 
discharges on the choice reaction time test; short term 
memory tests (verbal and non verbal) and on school 
performance tasks such as reading and writing. 
Generalized 3-HZ spike - wave bursts lasting at least 
3 s are most likely to produce demonstrable TCI, but 
they can also be found during briefer and even focal 
discharges. About one - half of children with subclinical 
discharges will show transient cognitive impairment 
during these discharges; those with predominantly 
left - sided discharges are weak in reading skills and 
those with right - sided discharges are weak in visual 
spatial tasks (5).
Other studies reported left sided focal spiking more 
frequently produces errors in verbal tasks, whereas 
right - sided discharges are accompanied more often by 
impairment in handling nonverbal material (6).
Increasing task difficulty, up to patients, limit 
of performance, was associated with increasing 
susceptibility to TCI. 
There are thus complex interactions of epileptiform EEG 
discharges on cognitive function.
The significance of transitory cognitive impairment 
accompanying subclinical EEG discharges for every 
day functioning is uncertain, but there is evidence that 
subclinical discharges may be accompanied by disruption 
of educational skills in children (3). In some individuals, 
suppression of discharges by antiepileptic drugs has 
demonstrably improved psychological function.
It seems early detection of the cognitive impact of seizure 
related activity and subsequent treatment may prevent 
its detrimental impact on cognitive and educational 
development, and is associated with significant 
improvement in psychosocial function (6). Suppression 
of the EEG discharges with antiepileptic drugs, viz. 
“Valproic Acid” “Lamotrigine” and “Carbamazepine” 
has been reported to improve cognitive performance in 
children (7).
Inutsuka and colleagues studied the effect of antiepileptic 
drugs in 15 patients on the EEG pattern of continuous 
spike-waves during slow wave sleep (CSWS) in 
15 patients. Therapies used included: 1. High dose 
valproate (VPA) therapy (serum level>100 microg/ml); 
MEDICAL THERAPY IN CHILDHOOD PSYCHO-COGNITIVE PROBLEMS 
9Iran J Child Neurology  Dec  2009
2. A combination therapy of VPA and ethosuximide 
(ESM); 3. Short cycles of high dose diazepam oral or 
intrarectal DZP,0.5-1 mg/kg per day for 6-7 days); and 
4. Intramuscular synthetic ACTH-Z therapy(0.01-0.04 
mg/kg per day for 11-43 days). Regarding the initial 
EEG effect, a remission of CSWS was achieved by 
high dose VPA therapy in 7 of 15 trials(47%), by the 
combination therapy of VPA and ESM in 3/7 trials 
(43%), by short cycles of high dose DZP in 2/4 trials 
(50%), and by ACTH-z therapy in 2/5 trials (40%). A 
permanent remission of ESES syndrome was achieved 
by high dose VPA therapy and/or combination therapy 
of VPA and ESM in 10 patients (67%)(8). 
In the Karimzadeh et al study, following 18 months of 
treatment, oral Na-Valproate was effective in improving 
the developmental behavioral condition of children 
with neurodevelopmental delay and subclinical EEG 
discharges (9).
In this study we recruited children who had behavioral-
cognitive problems, but did not have any organic brain 
disease and had normal results for paraclinical work up 
(including Neuroimaging, Genetic, Neurometabolic, 
Torch, etc). After 18 months of treatments all patients 
had normal EEG and they showed dramatic improvement 
in behavioral disorders such as aggressiveness, 
hyperactivity and attention deficit. Good results were 
also observed in sleep disorders of these children, who 
also showed improvement in their cognition and speech 
performance.
Autistic Regression Syndrome and Subclinical 
Epileptiform Activity
Subclinical epileptiform activity can generate autistic 
regression in children with pervasive developmental 
disorder (PDD). Electrographic status epileptiform in 
sleep, or continuous spike - wave in slow - wave sleep 
is a typical feature of acquired epileptic aphasia or 
Laundau - Klefner syndrome. Subclinical seizures 
and epileptiform activity, are more common among 
children with autistic spectrum disorder who experience 
language regression, especially in those who show this 
regression after the age of 2 years. It has been suggested 
that the suppression of subclinical epileptiform activity 
by the early use of antiepileptic drug (AED) can reverse 
disorders affecting behavior, cognition and language in 
these patients.
Studies have been conducted to examine the influence 
of AED therapy on the clinical course of children 
with PDD and autistic regression, with epileptiform 
discharge in their EEG, recorded during sleep. Drugs 
which could bring complete recovery or significant 
improvement include: Valproate, Ethosuximide, 
Clobazam, Oxcarbazepine, Sulthiame, Levetiracetam, 
Topiramate, Lamotrigine and courses of corticoids or 
ACTH (10,11).
Hollander and colleagues reported beneficial effects of 
divalproex sodium in autistic spectrum disorders. They 
used divalproex sodium in treating core dimensions 
and associated features of autism; asperger’s disorder 
or pervasive developmental disorders or EEG 
abnormalities.
Results revealed 71% of patients had sustained response 
to treatment (12).
Nonconvulsive Status Epilepticus and 
Neuro-developmental delay
Non convulsive status epilepticus, characterized 
by continuous epileptiform discharges on 
electroencephalography without motor or sensory 
phenomena, is a symptomatic condition related to disease 
such as epileptic encephalopathy or a metabolic disorder. 
Children with isolated non convulsive status epilepticus 
rarely present with global neurodevelopmental delay.
Non convulsive status epilepticus, an epileptic state 
consisting of a prolonged alteration in mental state or 
behavior, consists of different syndromes including 
typical absence status epilepticus, complex partial 
status epilepticus and non convulsive status epilepticus 
in patients with learning difficulties. Its diagnosis is 
dependent on electroencephalography and the syndromes 
have different prognosis and treatments (13).
Electrical status epilepticus during sleep is characterized 
by spike-and - wave discharges in non - rapid eye 
movement sleep.
Childhood non convulsive status epilepticus may 
occur as an isolated phenomenon. It is rare in infants 
but it should be kept in mind in differential diagnosis 
of neurodevelopmental delay. Treatment is useful to 
prevent the long term complication of the disease such 
as intellectual and cognition impairment and speech. 
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Compared to other drugs used in the management of non 
convulsive status epilepticus, such as Benzodiazepines, 
Valproate is more effective. Some studies revealed 
dramatic response with intravenous Na-Valproate in 
children with global developmental delay and isolated 
non convulsive status epilepticus (14).
Dirik and co-workers reported an 18-month-old male 
with isolated non convulsive status epilepticus who 
presented with global neurodevelopmental delay, 
which was treated with Valproic acid and the patient 
began to achieve developmental milestones after 
treatment (13).
In the Karimzadeh, et al study (under publication), high 
dose intravenous methyl - prednisolone was used in 
children with neurodevelopmental delay and electrical 
status epilepticus during slow - wave sleep without 
clinical seizure; after high dose Methyl Prednisolone 
therapy, Prednisolone was administered orally (2 mg/
kg daily) for 2 months, which was gradually withdrawn. 
In these children, results of appropriate metabolic tests, 
and magnetic resonance imaging of the brain revealed 
no abnormality. Since no underlying etiology was 
determined, isolated non convulsive status epilepticus 
was the diagnosis. No significant response was observed 
with administration of high dose methyl prednisolone in 
these children; after treatment, 30% of patients showed 
suppression of electrical status epilepticus during sleep, 
of whom only 7% showed improvement in cognition 
and their verbal communication. Among the remaining 
(70%) we had neither changes of  subclinical epileptiform 
discharges nor global developmental delay.
Okuyaz reported a 4-year-old female patient with 
continuous spike and waves during slow-wave sleep 
not classified as landau - klefnere syndrome, who 
was treated successfully with high-dose intravenous 
methylprednisolone therapy. After one week, a dramatic 
clinical and electroencephaloghraphic response was 
observed and after withdrawal of corticosteroid therapy, 
the patient maintained the clinical improvement in 
behavior. No continuous spike and wave electrical 
stastus epilepticus during slow wave sleep occurred 
on EEG for 6 months (14).
ADHD and Subclinical Epileptiform Discharges 
Evaluation of children with attention deficit 
hyperactivity syndromes and subclinical epileptiform 
discharges without seizure revealed a relation between 
subclinical epileptiform discharges and cognitive 
dysfunction. Treatment with Antiepileptic drugs (AED) 
in these children showed significant effectiveness of 
AED on attention deficit hyperactivity disorders and 
electroencephalographic discharges (15). 
Treatment 
Use of AEDs such as Valproate, Ethosuximide, 
Clobazam, Oxcarbazepine, Sulthiame, Levetiracetam, 
Topiramat, or Lamotrigine has been reported. In some 
studies, Valproate is reported to be more effective 
than other AED in cognition and behavioral disorder 
(7), whereas in others, sustained improvement with 
corticosteroids has been found. In these studies after 
high - dose intravenous methyl prednisolone, dramatic 
clinical and electroencephalographic responses were 
observed. In these children, after the withdrawal of 
corticosteroid therapy, the patients maintained the 
clinical improvement in behavior and no spike-wave 
discharges occurred on routine monthly EEG for the last 
6 months (14). 
Recent studies reported Lamotrigine, a new Antiepileptic 
drug, can be efficacious and well tolerated in patients with 
neurodevelopmental delay and behavioral disorder (16). 
Several studies have demonstrated favorable effects of 
Lamotrigine on psychological well-being that were not 
explained by simple effects on seizure frequency and its 
severity. In addition positive behavioral effects have also 
been observed in blinded studies and several open trials 
for patients with severe mental disability and refractory 
epilepsy(17,18).
Lamotrigine provides effective control of both overt 
and subclinical seizures, without adversely affecting 
cognition. According to the Karimzadeh et al study 
(under publication) Lamotrigine is used in children with 
neurodevelopmental delay with abnormal epileptiform 
discharges in EEG and without active seizures.
Results revealed Lamotrigine provides effective control 
of both subclinical epileptiform discharges and behavioral 
disorder, without therapeutic effects on cognition. It is 
well tolerated but further studies with more extensive 
psycho-behavioral assessment are needed to evaluate 
and confirm the cognitive and behavioral effects of 
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Lamotrigine in children with psychomotor retardation.
Conclusion 
Improving the neurodvelopmental disabilities of 
children referred to Pediatric Neurology Clinics is of 
critical importance, as such children may suffer from 
speech delay, intellectual deficiency and behavioral 
disorder. 
Many patients with neurodevelopomental delay 
especially those with intellectual disability and speech 
problems have abnormal electroencephalograms, some 
of these have abnormal EEG without clinical seizure.
It seems that Abnormal electrical discharges in these 
patients cause very short but recurrent impairment of 
consciousness, which can inhibit their desirable mental 
development.
Several studies reported the use of  AED may 
suppresse  these subclinical epileptiform discharges 
and improve of their developmental behavioral 
conditions.
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